LBA ASH22: Significantly better overall survival in patients with B-lineage ALL treated with Blincyto, blinatumomab, as Consolidation Therapy

As a late-breaking ASH22 abstract, Professor of Medicine at the Division of Hematology, Mayo Clinic, USA, Mark R. Litzow presented data from a phase III trial randomizing patients to conventional chemotherapy with or without blinatumomab to determine the overall survival of patients who become MRD negative (0.1%). The study demonstrates, that the combination chemotherapy with blinatumomab resulted in a significantly better overall survival in patients with newly diagnosed B-lineage ALL who were MRD negative after intensive chemotherapy.